Opinion - Page 53

WASHINGTON — The Food and Drug Administration is in a precarious position as it heads toward 2026.  The agency has been mired by high-profile departures, feuds between top leaders, accusations of politicization,

Despite uncertainty and concern buffeting Massachusetts hospitals, the state’s largest health system saw its finances improve last year, turning a small operating surplus and receiving a boon from investment income. Mass General Brigham

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. There’s a ton of news today. Make sure you keep scrolling for

WASHINGTON — The Centers for Disease Control and Prevention has awarded a $1.6 million grant to controversial researchers at the University of Southern Denmark with ties to top Food and Drug Administration official

OnPoint NYC, the nonprofit that was the first in the nation to openly offer supervised drug consumption services, celebrated its fourth anniversary Thursday by trumpeting its positive community impact, making its case

President Trump on Thursday signed an executive order directing the federal government to reclassify marijuana as a Schedule III substance, marking a major milestone in American drug policy and choosing sides in

The Trump administration is making its most forceful attempt yet at restricting gender-affirming care for transgender youth in the U.S. The Centers for Medicare and Medicaid Services proposed on Thursday two rules

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. If you haven’t seen Alex Hogan’s STATus Report video on the CDC vaccine

Eight years before Steward Health Care’s explosive, highly publicized collapse, the private equity-backed hospital chain sold its properties to a real estate investment trust. A new study adds weight to the widely-held

When HCA Healthcare, one of the largest hospital systems in the U.S., recently told employees it would stop covering blockbuster obesity drugs Zepbound and Wegovy next year, it pointed them to an